SCHEMBL3023608

SCHEMBL3023608

COc1cccc(C2(CC(=O)O)C3CC4CC(C3)CC2C4)c1

nearest known ligand 0.72

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 13/20 0.72
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.43
FAAH O00519 1/20 0.43
CNR2 P34972 1/20 0.43
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13216108 0.86 HSD11B1 (0.65) HSD11B1MEN1KMT2ATSHRLMNA
SCHEMBL13216367 0.86 HSD11B1 (0.59) HSD11B1MEN1KMT2AALDH1A1LMNA
SCHEMBL13216336 0.84 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL13216106 0.83 HSD11B1 (0.71) HSD11B1MEN1KMT2A
SCHEMBL13216407 0.83 HSD11B1 (0.62) HSD11B1
SCHEMBL6679459 0.82 HSD11B1 (0.47) HSD11B1MEN1KMT2AFAAHCNR2
SCHEMBL3025215 0.81 HSD11B1 (0.73) HSD11B1MEN1KMT2A
SCHEMBL7813280 0.80 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL13216326 0.80 HSD11B1 (1.00) HSD11B1MEN1KMT2A
SCHEMBL13216344 0.80 HSD11B1 (1.00) HSD11B1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054368-B1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
EP-2054368-B1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 EP disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-8299054-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-30 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
US-7727978-B2 Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-01 US disclosed
EP-2054368-A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS Brystol-Myers Squibb Company (US) 2009-05-06 EP disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-09-25 US disclosed
WO-2008024892-A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-28 WO disclosed
WO-2008024892-A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234249-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885
US-20100204199-A1 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MEN1 994/4885KMT2A 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.